List of Excipients in Branded Drug TRODELVY

Last updated: August 20, 2026

Trodelvy's excipient strategy is built around a conventional but commercially effective lyophilized antibody-drug conjugate formulation: histidine buffer, polysorbate 80, and trehalose dihydrate in a single-dose 180 mg vial. The main commercial opportunities are in high-purity biologic excipients, formulation-risk reduction, ready-to-administer presentations, infusion logistics, and next-generation delivery systems. Trodelvy's growing sales base and complex antibody-drug conjugate manufacturing create a higher-value excipient market than the small per-vial ingredient cost suggests.

Trodelvy Excipient Strategy and Commercial Opportunities

Trodelvy, or sacituzumab govitecan-hziy, is a Trop-2-directed antibody-drug conjugate marketed by Gilead Sciences. Its formulation uses a limited excipient system designed to preserve antibody integrity during lyophilization, storage, reconstitution, and intravenous infusion. The formulation is commercially important because Trodelvy is administered in oncology centers, has a weight-based dose, requires vial reconstitution, and depends on cold-chain distribution.

What excipients are used in Trodelvy?

The U.S. prescribing information identifies three inactive ingredients in the 180 mg lyophilized Trodelvy vial: histidine, polysorbate 80, and trehalose dihydrate.[1]

Excipient	Primary formulation function	Commercial relevance
Histidine	Buffering and pH control	High-purity, low-bioburden supply is important for biologics
Polysorbate 80	Surfactant; limits interfacial and agitation-related aggregation	Oxidation, degradation, and lot variability create supplier-selection risk
Trehalose dihydrate	Lyoprotectant and stabilizer	Supports the cake structure and protects the antibody-drug conjugate during freeze-drying

Each 180 mg vial contains approximately 4.5 mg histidine, 1.8 mg polysorbate 80, and 75 mg trehalose dihydrate, according to the FDA-approved labeling.[1] The product is reconstituted with sterile water for injection to produce a 10 mg/mL solution and is subsequently diluted for intravenous infusion.

The formulation does not use an unusual excipient platform. Its value lies in the interaction between the excipients, the antibody-drug conjugate, the lyophilization cycle, the vial system, and the handling conditions used by oncology providers.

How does Trodelvy's formulation work?

Trodelvy's formulation has to protect a chemically complex molecule rather than a conventional monoclonal antibody. The product combines an antibody, a hydrolysable linker, and SN-38, the active metabolite of irinotecan. Each component creates separate degradation risks.

Histidine buffer

Histidine is widely used in biologic formulations because it provides buffering across a biologically relevant pH range and can be compatible with monoclonal antibodies. In Trodelvy, histidine helps maintain the formulation environment during manufacture, freezing, storage, reconstitution, and infusion.

The commercial opportunity is not based on volume. Histidine demand per vial is low, but biologic manufacturers typically require tight controls on identity, purity, trace metals, endotoxins, particulates, and microbial contamination. Suppliers that can provide validated pharmaceutical-grade histidine with reliable global supply have greater value than commodity producers.

Polysorbate 80

Polysorbate 80 reduces adsorption to manufacturing equipment, vial surfaces, filters, and infusion components. It also limits aggregation caused by agitation and air-liquid interfaces.

Polysorbate 80 is a major formulation-risk point for biologics. Potential concerns include:

• Oxidative degradation;
• Peroxide formation;
• Hydrolysis of the ester bond;
• Subvisible particle formation;
• Interaction with stainless steel, elastomers, filters, and infusion bags;
• Lot-to-lot variation in fatty-acid composition.

For an antibody-drug conjugate, these risks can affect aggregate levels, potency, impurity profiles, and the stability of the linker-payload system. Suppliers with low-peroxide, low-particulate, and tightly characterized polysorbate 80 products can compete on quality and regulatory support rather than price alone.

Polysorbate 80 is also the excipient most likely to create a future differentiation opportunity. A supplier that can demonstrate improved oxidation control, lower hydrolysis, or better compatibility with ADCs could support formulation changes, lifecycle management, or manufacturing improvements.

Trehalose dihydrate

Trehalose acts primarily as a stabilizing sugar and lyoprotectant. During freeze-drying, it helps protect the antibody-drug conjugate against stresses caused by freezing and water removal. It also contributes to the physical structure and reconstitution behavior of the lyophilized cake.

Trehalose is a relatively established excipient, but pharmaceutical-grade supply still requires control of water content, impurities, endotoxins, particle properties, and microbial quality. Trehalose suppliers can create commercial value through:

• Consistent moisture specifications;
• Improved powder handling;
• Validated low-endotoxin grades;
• Global regulatory files;
• Reliable supply for commercial-scale lyophilization;
• Compatibility data for ADC manufacturing.

What is Trodelvy's dosage form and administration process?

Trodelvy is supplied as a single-dose, 180 mg lyophilized powder in a vial. The vial is reconstituted with sterile water for injection and diluted before intravenous administration.[1]

The product's administration workflow creates several excipient-adjacent commercial opportunities:

1. Reconstitution time and ease of use;
2. Foam control during preparation;
3. Low particulate generation;
4. Compatibility with infusion bags and tubing;
5. Stability after reconstitution and dilution;
6. Reduction of preparation waste;
7. Safe handling in oncology pharmacies.

The label permits dilution in 0.9% sodium chloride or 5% dextrose injection.[1] This dual-diluent compatibility expands hospital workflow options but also requires compatibility across common bags, tubing materials, filters, and administration sets.

The product's weight-based dosing can require multiple vials. At the approved 10 mg/kg dose administered on Days 1 and 8 of a 21-day cycle, patients may require different vial counts depending on body weight. Unused drug is discarded because the vial is single dose. That creates a commercial opening for higher-concentration presentations, optimized vial sizes, or ready-to-use infusion formats, although each option would require substantial comparability and regulatory work.

What commercial opportunities exist in Trodelvy excipients?

The largest opportunities are concentrated in specialized supply and formulation services rather than bulk excipient sales.

High-purity polysorbate 80

Polysorbate 80 is the strongest target for premium excipient suppliers. Demand can arise from:

• Low-peroxide grades;
• ADC-specific stability packages;
• Oxidation monitoring;
• Analytical methods for fatty-acid profile and degradation products;
• Qualified alternate suppliers;
• Co-development of more oxidation-resistant surfactant systems.

Potential substitutes include polysorbate 20, poloxamers, or newer surfactants. Substitution would not be a simple procurement change. It could affect aggregation, potency, extractables, adsorption, reconstitution, and the stability of the conjugated payload.

Trehalose and alternative lyoprotectants

Trehalose suppliers can compete by supporting higher-throughput lyophilization, faster reconstitution, and reduced cake defects. Alternative sugars or sugar-alcohol systems could be evaluated where they improve residual moisture, collapse temperature, or long-term stability.

A formulation change would face a high technical threshold. The sponsor would need to demonstrate that the alternative maintains:

• Antibody binding;
• Drug-to-antibody ratio distribution;
• Linker stability;
• Free payload control;
• Aggregation profile;
• Potency;
• Sterility and particulate specifications.

Ready-to-use and concentrated presentations

A liquid formulation, concentrated vial, or pre-diluted infusion product could reduce pharmacy preparation steps. The opportunity is commercially attractive because Trodelvy is used in hospital and outpatient infusion settings.

The barriers are substantial:

• Liquid stability may be inferior to the lyophilized format;
• Polysorbate degradation may accelerate during extended storage;
• The antibody-drug conjugate may be more sensitive to hydrolysis;
• Container closure and adsorption risks may increase;
• A new presentation would require comparability and regulatory review.

A ready-to-use product could support lifecycle management, reduce preparation errors, and improve site-of-care economics even if the per-dose ingredient cost remains unchanged.

Infusion components and packaging

Trodelvy-related commercial opportunities extend beyond the vial. Relevant products include:

• Low-binding tubing;
• Compatible infusion bags;
• Low-shedding stoppers;
• Silicone-control technologies;
• Sterile transfer devices;
• Closed-system drug-transfer devices;
• Validated filters;
• Oncology pharmacy compounding systems.

Packaging suppliers that provide complete compatibility packages can compete more effectively than those selling a single component. The technical objective is to minimize adsorption, particles, drug loss, and exposure during reconstitution and infusion.

How strong is the excipient IP position for Trodelvy?

Trodelvy's core commercial protection is centered on the antibody-drug conjugate, its target, linker-payload configuration, manufacturing methods, and clinical uses. The three listed excipients are established pharmaceutical materials and are unlikely to provide broad standalone exclusivity.

Excipient-related protection may arise through:

• Specific concentration ranges;
• pH and buffer conditions;
• Lyophilization cycles;
• Reconstitution methods;
• Stability specifications;
• Container-closure systems;
• Infusion compatibility;
• Alternative surfactant or sugar combinations;
• Manufacturing methods that reduce degradation.

Because Trodelvy is a biologic licensed under a BLA, it does not have the same Orange Book listing framework as a small-molecule drug. Patent information should be assessed separately from Orange Book status. Biosimilar applicants would need to establish product similarity and address formulation, analytical, manufacturing, and clinical comparability issues under the Public Health Service Act pathway.[2]

The formulation is therefore commercially defensible through technical complexity and manufacturing knowledge, not only through excipient composition claims. A competitor may be able to use the same excipients while still facing difficulty reproducing the full product quality profile.

When does Trodelvy lose exclusivity?

Trodelvy's exclusivity timeline is determined by biologic regulatory exclusivity, patents, pediatric exclusivity, and any litigation or settlement outcomes. The FDA approved Trodelvy in April 2020 under the accelerated approval pathway for metastatic triple-negative breast cancer and converted the approval to regular approval in April 2021 after confirmatory evidence.[3]

The FDA later approved Trodelvy for adult patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer after endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.[4]

Protection category	Trodelvy relevance
BLA biologic exclusivity	Applies to the reference biologic under the statutory biosimilar framework
Orange Book	Not the primary listing mechanism for Trodelvy
Purple Book	Relevant FDA reference for biologic reference-product and biosimilar information
Composition and ADC patents	May cover the conjugate, linker, payload, antibody, or target
Method-of-use patents	May cover cancer indications, dosing, sequencing, or patient populations
Formulation patents	May cover concentrations, buffers, stabilizers, lyophilization, or administration
Manufacturing patents	May cover conjugation, purification, drug-to-antibody ratio control, or process conditions

A biosimilar or interchangeable product cannot be assessed solely from the expiration of one patent. The practical entry date depends on the remaining patent estate, regulatory exclusivity, manufacturing readiness, litigation, and the applicant's willingness to launch at risk.

What generic and biosimilar entry risks exist for Trodelvy?

Traditional generic entry is not the relevant risk. Trodelvy is a complex biologic ADC, so the principal threat is biosimilar or follow-on biologic competition.

The technical barriers are higher than for a conventional monoclonal antibody because a competitor must characterize:

• Antibody sequence and higher-order structure;
• Drug-to-antibody ratio;
• Payload distribution;
• Conjugation-site profile;
• Linker stability;
• Free SN-38 and related impurities;
• Glycosylation;
• Aggregation;
• Binding and internalization;
• Cytotoxic potency;
• Pharmacokinetic behavior.

The excipient system may be copied or modified, but a modified formulation could create a separate comparability burden. A biosimilar sponsor could seek a formulation with a different buffer, surfactant, sugar, vial size, or concentration. That approach may reduce dependence on Trodelvy's formulation patents but would increase development and regulatory risk.

What is Trodelvy's FDA and commercial status?

Trodelvy is FDA-approved for specified breast cancer populations and is administered intravenously. The product is marketed by Gilead Sciences through its oncology portfolio.[1,3,4]

Gilead reported Trodelvy product sales of approximately $1.1 billion in 2024, compared with approximately $1.08 billion in 2023.[5] This revenue base makes excipient and presentation improvements commercially relevant even when the excipient cost per vial is small.

Potential revenue-sensitive opportunities include:

• Lowering vial overfill and discarded drug;
• Increasing stability after reconstitution;
• Reducing pharmacy labor;
• Supporting outpatient infusion;
• Improving cold-chain robustness;
• Reducing infusion-component incompatibility;
• Extending supply reliability across regions.

An excipient change that reduces waste by even a modest percentage could have economic value because oncology ADC doses are high cost and often require multiple vials per administration.

How does Trodelvy compare with other antibody-drug conjugates?

Trodelvy's excipient strategy is broadly consistent with commercial ADC practice: a lyophilized product, a stabilizing sugar, a buffering agent, and a nonionic surfactant. The differentiating issue is not whether the ingredients are novel. It is whether the combination delivers acceptable stability for a conjugate containing a hydrolysable linker and SN-38 payload.

Compared with liquid monoclonal antibodies, Trodelvy has greater formulation complexity because it must preserve both antibody behavior and payload-linker integrity. Compared with small-molecule oncology drugs, it also has greater dependence on cold chain, sterile manufacturing, container compatibility, and infusion operations.

The strongest competitive advantage is likely to come from process control and product presentation rather than from proprietary access to histidine, polysorbate 80, or trehalose.

What manufacturing and geographic barriers affect Trodelvy excipients?

Trodelvy requires a qualified supply chain for biologic-grade excipients and sterile drug-product manufacturing. Geographic risks include:

• Concentration of high-quality polysorbate production;
• Limited suppliers with validated ADC experience;
• Import and customs delays;
• Regional differences in compendial requirements;
• Cold-chain interruptions;
• Variability in hospital diluent and infusion systems;
• Limited local capacity for sterile lyophilization.

A dual-source strategy is most valuable for polysorbate 80 and other materials with known degradation or supply risks. Qualification of an alternate source can take significant time because the sponsor must assess material comparability, process impact, analytical methods, stability, and regulatory reporting requirements.

For suppliers, the best entry strategy is to sell a validated package consisting of excipient material, impurity controls, stability data, and regulatory documentation. Price competition alone is unlikely to displace an incumbent supplier in a commercial ADC process.

Key Takeaways

• Trodelvy uses histidine, polysorbate 80, and trehalose dihydrate in a 180 mg lyophilized vial.
• Polysorbate 80 is the most commercially attractive excipient because oxidation, hydrolysis, and lot variability can affect ADC quality.
• Trehalose and histidine are established materials, but high-purity, low-endotoxin, globally qualified supply remains valuable.
• The main lifecycle opportunity is a ready-to-use, concentrated, or more stable presentation that reduces pharmacy labor and vial waste.
• Trodelvy is a biologic, so biosimilar risk is more relevant than traditional generic substitution.
• Trodelvy does not rely on Orange Book listing as the primary exclusivity framework.
• Excipient IP is likely to be narrower than ADC composition, method-of-use, and manufacturing protection.
• Commercial opportunity is concentrated in formulation services, packaging, infusion compatibility, analytical control, and supply-chain resilience.
• Gilead's roughly $1.1 billion in 2024 Trodelvy sales supports investment in formulation and administration improvements.

FAQs

Can polysorbate 80 be replaced in Trodelvy?

Yes, replacement is technically possible, but a new surfactant would require extensive comparability testing covering aggregation, potency, payload stability, particulates, reconstitution, and infusion compatibility.

Could Trodelvy be converted from a lyophilized powder to a liquid vial?

Potentially, but liquid conversion would create new stability risks for the antibody-drug conjugate, linker, payload, surfactant, and container-closure system. It would require a major lifecycle-development program.

Are Trodelvy's excipients patent-protected as standalone ingredients?

Histidine, polysorbate 80, and trehalose are established pharmaceutical excipients. Protection is more likely to involve their use in a specific Trodelvy formulation, concentration range, lyophilization process, or administration system.

Does Trodelvy have a traditional generic drug pathway?

No. Trodelvy is a biologic ADC regulated through a BLA. Competitive entry would generally involve a biosimilar or other follow-on biologic pathway rather than an ANDA generic pathway.

Which excipient supplier has the greatest Trodelvy opportunity?

Suppliers with low-peroxide polysorbate 80, ADC-specific stability data, validated pharmaceutical-grade trehalose, and global regulatory support have the strongest positioning. Integrated formulation and analytical services provide a stronger commercial proposition than bulk ingredient supply alone.

References

1. U.S. Food and Drug Administration. (2024). Trodelvy (sacituzumab govitecan-hziy) prescribing information. Gilead Sciences, Inc.

2. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov

3. U.S. Food and Drug Administration. (2021). FDA grants regular approval to sacituzumab govitecan for metastatic triple-negative breast cancer. https://www.fda.gov

4. U.S. Food and Drug Administration. (2023). FDA approves sacituzumab govitecan-hziy for breast cancer. https://www.fda.gov

5. Gilead Sciences, Inc. (2025). 2024 annual report. Gilead Sciences, Inc.